Angiotensin-converting enzyme 2 (ACE2) activator DIZE ameliorates endotoxin-induced uveitis in mice

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 6, 2014, Pages 3809-3818

  Qiu, Yiguo ^a,b   Shil, Pollob Kumar ^a   Zhu, Ping ^a   Yang, Hongxia ^b   Verma, Amrisha ^a   Lei, Bo ^b   Li, Qiuhong ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme 2; Diminazene aceturate; EIU; Renin angiotensin system; Uveitis

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIMINAZENE ACETURATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HYPEREMIA; IMMUNE RESPONSE; INFLAMMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SEQUENCE ANALYSIS; SLIT LAMP; UVEITIS;

ANGIOTENSIN-CONVERTING ENZYME 2; DIMINAZENE ACETURATE; EIU; RENIN ANGIOTENSIN SYSTEM; UVEITIS;

ANIMALS; ANTERIOR EYE SEGMENT; DIMINAZENE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; FOLLOW-UP STUDIES; INTERCALATING AGENTS; MICE; MICE, INBRED BALB C; OPHTHALMIC SOLUTIONS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM; UVEITIS;

EID: 84902656183     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-13883     Document Type: Article

References (54)

1. Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23:705-717.
2. Read RW. Uveitis: advances in understanding of pathogenesis and treatment. Curr Rheumatol Rep. 2006;8:260-266.
3. Munoz-Fernandez S, Martin-Mola E. Uveitis. Best Pract Res Clin Rheumatol. 2006;20:487-505.
4. Tabbara KF. Infectious uveitis: a review. Arch Soc Esp Oftalmol. 2000;75:215-259.
5. Servat JJ, Mears KA, Black EH, Huang JJ. Biological agents for the treatment of uveitis. Expert Opin Biol Ther. 2012;12:311-328.
6. Gomes Bittencourt M, Sepah YJ, Do DV. et al. New treatment options for noninfectious uveitis. Dev Ophthalmol. 2012;51: 134-161.
7. Rosenbaum JT, Rosenzweig HL, Smith JR, Martin TM, Planck SR. Uveitis secondary to bacterial products. Ophthalmic Res. 2008;40:165-168.
8. Hoekzema R, Murray PI, van Haren MA, Helle M, Kijlstra A. Analysis of interleukin-6 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1991;32:88-95.
9. Koizumi K, Poulaki V, Doehmen S, et al. Contribution of TNFalpha to leukocyte adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci. 2003;44:2184-2191.
10. Tuaillon N, Shen DF, Berger RB, et al. MCP-1 expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2002; 43:1493-1498.
11. Becker MD, Garman K, Whitcup SM, Planck SR, Rosenbaum JT. Inhibition of leukocyte sticking and infiltration, but not rolling, by antibodies to ICAM-1 and LFA-1 in murine endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 2001; 42:2563-2566.
12. Miyamoto K, Ogura Y, Hamada M, et al. In vivo quantification of leukocyte behavior in the retina during endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1996;37:2708-2715.
13. Yamashiro K, Kiryu J, Tsujikawa A, et al. Suppressive effects of selectin inhibitor SKK-60060 on the leucocyte infiltration during endotoxin induced uveitis. Br J Ophthalmol. 2003;87: 476-480.
14. Herichova I, Szantoova K. Renin-angiotensin system: upgrade of recent knowledge and perspectives. Endocr Regul. 2013; 47:39-52.
15. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
16. Campbell DJ. Evolving concepts of the renin angiotensin system. Clin Exp Pharmacol Physiol. 2013;40:525-526.
17. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens. 2001;10:321-329.
18. Luft FC, Dechend R, Muller DN. Immune mechanisms in angiotensin II-induced target-organ damage. Ann Med. 2012; 44(suppl 1):S49-S54.
19. Nagai N, Oike Y, Noda K, et al. Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci. 2005;46:2925-2931.
20. da Cunha V, Tham DM, Martin-McNulty B, et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis. 2005;178:9-17.
21. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensinconverting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
22. Passos-Silva DG, Verano-Braga T, Santos RA. Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci (Lond). 2013;124: 443-456.
23. Simoes e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169:477-492.
24. Verma A, Shan Z, Lei B, et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther. 2012;20:28-36.
25. Gjymishka A, Kulemina LV, Shenoy V, Katovich MJ, Ostrov DA, Raizada MK. Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug. FASEB J. 2010;24:1032.3.
26. Shenoy V, Gjymishka A, Jarajapu YP, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187:648-657.
27. Mecca AP, Regenhardt RW, O'Connor TE, et al. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084-1096.
28. Foureaux G, Nogueira JC, Nogueira BS, et al. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Invest Ophthalmol Vis Sci. 2013;54:4296-4306.
29. Yang P, Smith JR, Damodar KS, Planck SR, Rosenbaum JT. Visualization of cell death in vivo during murine endotoxininduced uveitis. Invest Ophthalmol Vis Sci. 2003;44:1993-1997.
30. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35:881-900.
31. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152-158.
32. Costanzo A, Moretti F, Burgio VL, et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol. 2003;195:402-410.
33. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247-257.
34. da Silveira KD, Coelho FM, Vieira AT, et al. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol. 2010;185: 5569-5576.
35. Sacca R, Cuff CA, Ruddle NH. Mediators of inflammation. Curr Opin Immunol. 1997;9:851-857.
36. McMenamin PG, Crewe J. Endotoxin-induced uveitis. Kinetics and phenotype of the inflammatory cell infiltrate and the response of the resident tissue macrophages and dendritic cells in the iris and ciliary body. Invest Ophthalmol Vis Sci. 1995;36:1949-1959.
37. Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:281-286.
38. Fujihara M, Muroi M, Tanamoto K, et al. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther. 2003;100:171-194.
39. Souza LL, Costa-Neto CM. Angiotensin-(1-7) decreases LPSinduced inflammatory response in macrophages. J Cell Physiol. 2012;227:2117-2122.
40. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92:689-737.
41. Rao KM, Meighan T, Bowman L. Role of mitogen-activated protein kinase activation in the production of inflammatory mediators: differences between primary rat alveolar macrophages and macrophage cell lines. J Toxicol Environ Health A. 2002;65:757-768.
42. El-Hashim AZ, Renno WM, Raghupathy R, et al. Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2-and NF-kappaB-dependent pathways. Br J Pharmacol. 2012;166:1964-1976.
43. Kuriakose S, Muleme H, Onyilagha C, Okeke E, Uzonna JE. Diminazene aceturate (Berenil) modulates LPS induced proinflammatory cytokine production by inhibiting phosphorylation of MAPKs and STAT proteins [published online ahead of print October 31, 2013]. Innate Immun. doi:10.1177/ 1753425913507488.
44. Marian AJ. The discovery of the ACE2 gene. Circ Res. 2013; 112:1307-1309.
45. Qi Y, Zhang J, Cole-Jeffrey CT, et al. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension. 2013;62:746-752.
46. Kuriakose S, Muleme HM, Onyilagha C, et al. Diminazene aceturate (Berenil) modulates the host cellular and inflammatory responses to Trypanosoma congolense infection. PLoS One. 2012;7:e48696.
47. Yaghooti H, Firoozrai M, Fallah S, Khorramizadeh MR. Angiotensin II induces NF-kappaB, JNK and p38 MAPK activation in monocytic cells and increases matrix metalloproteinase-9 expression in a PKC-and Rho kinase-dependent manner. Braz J Med Biol Res. 2011;44:193-199.
48. Rajapurohitam V, Kilic A, Javadov S, Karmazyn M. Role of NFkappaB and p38 MAPK activation in mediating angiotensin II and endothelin-1-induced stimulation in leptin production and cardiomyocyte hypertrophy. Mol Cell Biochem. 2012;366: 287-297.
49. Peregrine AS, Mamman M. Pharmacology of diminazene: a review. Acta Trop. 1993;54:185-203.
50. Vaajanen A, Lakkisto P, Virtanen I, et al. Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmol. 2009;88:431-438.
51. Luhtala S, Vaajanen A, Oksala O, Valjakka J, Vapaatalo H. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther. 2009;25:23-28.
52. Senanayake P, Drazba J, Shadrach K, et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci. 2007;48:3301-3311.
53. Sukumaran V, Veeraveedu PT, Gurusamy N, et al. Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis. Life Sci. 2012;90:289-300.
54. Sukumaran V, Veeraveedu PT, Gurusamy N, et al. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int J Biol Sci. 2011;7:1077-1092.